GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We are making steady progress as it relates to AD04. We have initiated new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3074668 State ...

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagno ...

公司业绩 - Adial Pharmaceuticals Inc (NASDAQ: ADIL) 今日股价上涨60%，因为其酒精障碍药物取得了令人期待的进展[1] - 公司总部位于弗吉尼亚州，美国，表示其AD04在酒精使用障碍（AUD）患者的临床试验中表现良好，口服低剂量的首席新药也没有产生任何不良影响[2] - Adial Pharmaceuticals股票在今天早上急剧上涨，但与年初高点相比下跌了40%[3] - Adial Pharmaceuticals报告称，AD04患者的遵从度高，辍学率明显降低[6] 潜在市场 - AUD是酒精相关肝病的主要贡献因素，Adial首席执行官表示AD04可能为AUD患者量身定制的精准治疗铺平道路，提供一种新颖的策略来管理饮酒并减轻肝脏损伤[7] 投资者关注 - 机构投资者包括Renaissance Technologies和Virtu Financial最近宣布持有Adial Pharmaceuticals股票，华尔街目前评级为“买入”[8]

Adial Pharmaceuticals (NASDAQ:ADIL) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder (AUD) treatment. This peer review focuses on Phase 3 clinical trial results for AD04. The article highlights the positive performance of the treatment as well as the safety data. The publication behind this article is the European Journal of Internal Medicine. Adial Pharmaceuticals CEO Cary Claiborne said the following about the peer-reviewed results. “Most impor ...

GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company's lead investigational new drug produ ...

Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business u ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-3074668 (State or Other Jurisdiction of Inco ...

公司交易协议 - Adial Pharmaceuticals, Inc.宣布与某些未行使的认股权证签订最终协议[1] - 公司预计从认股权证行使中获得的总收益为$3,530,500[2] - 公司将发行新的未注册认股权证，以换取现金行使认股权证[3] - 公司打算将净收益用于一般企业用途，包括一般和行政费用、营运资金以及支持AD04相关的监管和临床活动[4]

CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office. The patent covers the Company's lead investigational new drug product, AD04, and its ability to target the ser ...